Number of medical studies in the Netherlands has fallen sharply
The number of commercial clinical trials in the Netherlands has decreased by 46 percent over the past four years. This is according to recent figures on the medical sector. This sharp decline is causing concern among experts, as clinical trials are essential for the development of new medicines and treatments for patients.
According to analysts, there are several reasons for this negative trend. An important factor is the changing international market. Developments in China and the policy of the United States, under the leadership of Donald Trump, have a major influence on where pharmaceutical companies conduct their research. As a result, the Netherlands seems to be becoming less attractive as a location for these projects.
The decline in clinical studies could have long-term consequences for Dutch healthcare. When less research takes place, patients in the Netherlands have less rapid access to the latest innovative therapies. Moreover, the Netherlands is losing part of its position as an international hub for medical innovation and science.
The sector is calling for action to stop the decline. Ways to improve the business climate for medical research in the Netherlands are being explored. It remains to be seen whether new measures can ensure that pharmaceutical companies choose the Netherlands more often as a location for their clinical trials again.